Why the study?
Does paclitaxel as a single agent improve response rates in patients with angiosarcoma of the scalp or face?
Population
9 patients with angiosarcoma of the scalp or face treated at Memorial Sloan-Kettering Cancer Center between…
Design
Case_series
Authors
Loading...
May support paclitaxel in scalp/face angiosarcoma; hypothesis-generating case series leaves open need for prospective trials.
Does paclitaxel as a single agent improve response rates in patients with angiosarcoma of the scalp or face?
Paclitaxel as a single agent demonstrates substantial activity and high major response rates in patients with angiosarcoma of the scalp or face.
Fata et al. (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: